LifeMap Sciences’ Integrated Biomedical Knowledgebase and Premium Tools for Empowered life Sciences Research


LifeMap NGS Variant Gene Biological Interpretation & Prioritization

Rapid biological interpretation & prioritization of variant genes from next generation sequencing data using

 

 

Powered by the GeneCards Suite integrated biomedical knowledgebase

Learn More...


LifeMap RNAseq & Microarray Gene Set Analysis

Identify in seconds:

Cells, tissue types and various human diseases that match experimental gene sets - based on shared similar gene expression patterns.

Diseases, biological pathways and compounds that are associated with experimental gene sets - based on shared gene functionality. 

 

Powered by the GeneCards Suite integrated biomedical knowledgebase

Learn More...


GeneCards Suite Integrated Biomedical Knowledgebase

Effectively navigate the universe of biological entities - genes, proteins, cells, biological pathways and diseases, and the connections between them.

Learn More...

Press

25 February 2015

LifeMap Sciences Partners with Toldot Genetics to Support Next Generation Sequencing Variant Analysis Commercialization

LifeMap Sciences, Inc. (LifeMap), a subsidiary of BioTime, Inc., announced today a commercial partnership agreement with Toldot Genetics, LTD (Toldot), a subsidiary of BATM Advanced Communications, Ltd. LifeMap’s GeneCards Suite, comprised of the company’s integrated biomedical knowledgebase and premium analysis tools, will optimize Toldot’s next generation sequencing (NGS) data analysis capabilities by powering its algorithm-based tools for assigning genetic variations derived from whole genome and exome sequencing, to clinical conditions in order to improve biomedical research. LifeMap will also promote Toldot’s products and offer them to its large user base of life scientists in academia, research hospitals, and biopharma.

Read more
Featured Customers
LifeMap’s products are used in more than 3,000 institutions in academia, research hospitals, national patent offices, and leading biopharma and diagnostic companies, including: